• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·NVOS
Share

Novo Integrated Sciences, Inc. Stocks

$ 0Last Updated 26.10.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 11838

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Novo Integrated Sciences, Inc. (NVOS) delivers a diverse array of primary healthcare services and related products through its two primary operational segments: Healthcare Services and Product Manufacturing and Development. The company's extensive service portfolio includes various therapeutic approaches such as physiotherapy, chiropractic care, manual manipulation, occupational therapy, and massage therapy. They also offer specialized treatments like acupuncture, functional dry needling, chiropody, and advanced rehabilitation for stroke, traumatic brain injuries, and other neurological conditions. Additionally, NVOS provides kinesiology, vestibular therapy, concussion management, and baseline testing, alongside unique programs like trauma-sensitive yoga and meditation for brain injury recovery and PTSD. Women's pelvic health, sports medicine, assistive device provision, dietetics, holistic nutrition, fall prevention education, sports team conditioning, and private personal training are also part of their offerings. Novo Integrated Sciences, Inc. is dedicated to the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of a wide range of orthopedic, musculoskeletal, sports injury, and neurological conditions. These services are provided across all age demographics, from pediatric and adult patients to geriatric populations. For older adults, the company offers comprehensive eldercare physiotherapy within long-term care homes, retirement communities, and through community-based home care. This includes group exercise classes and fall prevention initiatives, alongside services at outpatient clinics. Similarly, occupational therapy services for the elderly are extended to retirement communities and long-term care facilities. Beyond direct care, the company incorporates medical technology, offering telemedicine consultations and remote patient monitoring. It also actively develops and distributes bespoke health and wellness product solutions. NVOS operates a network of 16 wholly-owned clinics. Established in 2000, the company is headquartered in Bellevue, Washington, and operates as a subsidiary of ALMC-ASAP Holdings, Inc.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.10.2026 01:34

Microsoft Exceeded Forecasts for Revenue Growth from Cloud Services

29.10.2026 01:17

Alphabet shares fell 7%: revenue and earnings came in below expectations

29.10.2026 01:07

The U.S. Federal Reserve will reduce the number of interest rate meetings starting in 2027

29.10.2026 00:35

Is this the end of the “Magnificent Seven”? Big Tech stocks have diverged in their performance. Which ones should you choose?

29.10.2026 00:10

Oracle surprised the market with its cash flow forecast. Its shares soared 12%.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026